Relevant immunological laboratory results are summarized in Table 1 and indicated that the patient had no detectable IgA and very low levels across all IgG subclasses. Additional laboratory values ...

they were randomized 1:1 to receive either subcutaneous or intravenous darbepoetin alfa once a week for 20 weeks before being crossed over to the other study regimen for a further 20 weeks.

it's a relief for Argenx that its subcutaneous version of Vyvgart was found to be as effective as the IV form at reducing levels of malfunctioning immunoglobulin G antibodies that cause weakness ...

The new guideline includes evidence-based recommendations for the use of subcutaneous immunoglobulin (SCIg ... their treatment at home with no IV access necessary, and potentially fewer systemic ...

compared with weekly multisite injections required for SC immunoglobulin formulated without ENHANZE 3. “ENHANZE has become the industry go-to technology for converting intravenous therapies to ...